Symptoms of overdose include convulsions, muscle weakness and confusion.
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Arsenic trioxide. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Arsenic trioxide. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Arsenic trioxide. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Arsenic trioxide. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Arsenic trioxide. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Arsenic trioxide. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Arsenic trioxide. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Arsenic trioxide. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Arsenic trioxide. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Arsenic trioxide. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Arsenic trioxide. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Arsenic trioxide. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Arsenic trioxide. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Arsenic trioxide. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Arsenic trioxide. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Arsenic trioxide. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Arsenic trioxide. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Arsenic trioxide. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Arsenic trioxide. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Arsenic trioxide. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Arsenic trioxide. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Arsenic trioxide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Arsenic trioxide. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Arsenic trioxide. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Arsenic trioxide. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Arsenic trioxide. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Arsenic trioxide. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Arsenic trioxide. |
| Cladribine | Arsenic trioxide may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Arsenic trioxide. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Arsenic trioxide. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Arsenic trioxide. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Arsenic trioxide. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Arsenic trioxide. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Arsenic trioxide. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Arsenic trioxide. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Arsenic trioxide. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Arsenic trioxide. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Arsenic trioxide. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Arsenic trioxide. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Arsenic trioxide. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Arsenic trioxide. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Arsenic trioxide. |
| Sorafenib | The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Arsenic trioxide. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Arsenic trioxide. |
| Betamethasone | The risk or severity of adverse effects can be increased when Betamethasone is combined with Arsenic trioxide. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Arsenic trioxide. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Arsenic trioxide. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Arsenic trioxide. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Arsenic trioxide. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Arsenic trioxide. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Arsenic trioxide. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Arsenic trioxide. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Arsenic trioxide. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Arsenic trioxide. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Arsenic trioxide. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Arsenic trioxide. |
| Methotrexate | The risk or severity of adverse effects can be increased when Methotrexate is combined with Arsenic trioxide. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Arsenic trioxide. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Arsenic trioxide. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Arsenic trioxide. |
| Imatinib | The risk or severity of adverse effects can be increased when Imatinib is combined with Arsenic trioxide. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Triamcinolone is combined with Arsenic trioxide. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Arsenic trioxide. |
| Prednisone | The risk or severity of adverse effects can be increased when Prednisone is combined with Arsenic trioxide. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Arsenic trioxide. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Arsenic trioxide. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Arsenic trioxide. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daunorubicin is combined with Arsenic trioxide. |
| Tretinoin | The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Arsenic trioxide. |
| Irinotecan | The risk or severity of adverse effects can be increased when Irinotecan is combined with Arsenic trioxide. |
| Methimazole | The risk or severity of adverse effects can be increased when Methimazole is combined with Arsenic trioxide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Arsenic trioxide. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Arsenic trioxide. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Arsenic trioxide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Arsenic trioxide. |
| Prednisolone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Arsenic trioxide. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Arsenic trioxide. |
| Azacitidine | The risk or severity of adverse effects can be increased when Azacitidine is combined with Arsenic trioxide. |
| Carboplatin | The risk or severity of adverse effects can be increased when Carboplatin is combined with Arsenic trioxide. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Arsenic trioxide. |
| Cytarabine | The risk or severity of adverse effects can be increased when Cytarabine is combined with Arsenic trioxide. |
| Azathioprine | The risk or severity of adverse effects can be increased when Azathioprine is combined with Arsenic trioxide. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Arsenic trioxide. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Arsenic trioxide. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Arsenic trioxide. |
| Thalidomide | The risk or severity of adverse effects can be increased when Thalidomide is combined with Arsenic trioxide. |
| Melphalan | The risk or severity of adverse effects can be increased when Melphalan is combined with Arsenic trioxide. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fludarabine is combined with Arsenic trioxide. |
| Flucytosine | The risk or severity of adverse effects can be increased when Flucytosine is combined with Arsenic trioxide. |
| Capecitabine | The risk or severity of adverse effects can be increased when Capecitabine is combined with Arsenic trioxide. |
| Trilostane | The risk or severity of adverse effects can be increased when Trilostane is combined with Arsenic trioxide. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Idarubicin. |
| Ifosfamide | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ifosfamide. |
| Estramustine | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Estramustine. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Mitoxantrone. |
| Lomustine | The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Lomustine. |